ITA4114
ITA4114
- Catalog: ITA4114
- Gene/Protein: ADARB1
- Product Description: Immunotag™ ADARB1 Antibody
385.0000
Price in reward points: 385
| Antibody Specification | |
| Datasheet |
|
| Target Protein | ADARB1 |
| Clonality | Polyclonal |
| Storage/Stability | -20°C/1 year |
| Application | WB,IF/ICC,ELISA |
| Recommended Dilution | WB 1:500~1:1000, IF/ICC 1:100-1:500 |
| Concentration | 1 mg/ml |
| Reactive Species | Human,Mouse,Rat |
| Host Species | Rabbit |
| Immunogen | A synthesized peptide |
| Specificity | ADARB1 Antibody detects endogenous levels of total ADARB1 |
| Purification | The antiserum was purified by peptide affinity chromatography. |
| Form | Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.Store at -20 °C.Stable for 12 months from date of receipt |
| Gene Name | ADARB1 |
| Accession No. | P78563 |
| Alternate Names | ADARB 1; ADARB1; 1700057H01Rik; ADAR2; ADAR2a; ADAR2a L1; ADAR2a L2; ADAR2a L3; ADAR2b; ADAR2c; ADAR2d; ADAR2g; Adarb1; Adenosine deaminase, RNA specific, 2; Adenosine deaminase, RNA specific, B1 (homolog of rat RED1); Adenosine deaminase, RNA specific, B1 (RED1 homolog rat); Adenosine deaminase, RNA specific, B1; AW124433; AW558573; BB220382; D10Bwg0447e; Double stranded RNA specific editase 1; Double-stranded RNA-specific editase 1; DRABA2; DRADA2; dsRNA adenosine deaminase; EC 3.5.-.-; Human dsRNA adenosine deaminase DRADA2; Human dsRNA adenosine deaminase DRADA2b, EC 3.5; OTTHUMP00000115341; OTTHUMP00000115342; RED 1; RED1_HUMAN; RNA editase; RNA editase 1; RNA editing deaminase 1; RNA editing enzyme 1; RNA editing enzyme 1, rat, homolog of; RNA specific adenosine deaminase B1; RNA-editing deaminase 1; RNA-editing enzyme 1; |
| Description | Catalyzes the hydrolytic deamination of adenosine to inosine in double-stranded RNA (dsRNA) referred to as A-to-I RNA editing. This may affect gene expression and function in a number of ways that include mRNA translation by changing codons and hence the amino acid sequence of proteins; pre-mRNA splicing by altering splice site recognition sequences; RNA stability by changing sequences involved in nuclease recognition; genetic stability in the case of RNA virus genomes by changing sequences during viral RNA replication; and RNA structure-dependent activities such as microRNA production or targeting or protein-RNA interactions. Can edit both viral and cellular RNAs and can edit RNAs at multiple sites (hyper-editing) or at specific sites (site-specific editing). Its cellular RNA substrates include: bladder cancer-associated protein (BLCAP), neurotransmitter receptors for glutamate (GRIA2 and GRIK2) and serotonin (HTR2C), GABA receptor (GABRA3) and potassium voltage-gated channel (KCNA1). Site-specific RNA editing of transcripts encoding these proteins results in amino acid substitutions which consequently alter their functional activities. Edits GRIA2 at both the Q/R and R/G sites efficiently but converts the adenosine in hotspot1 much less efficiently. Can exert a proviral effect towards human immunodeficiency virus type 1 (HIV-1) and enhances its replication via both an editing-dependent and editing-independent mechanism. The former involves editing of adenosines in the 5'UTR while the latter occurs via suppression of EIF2AK2/PKR activation and function. Can inhibit cell proliferation and migration and can stimulate exocytosis. |
| Cell Pathway/ Category | Primary Polyclonal Antibody |
| Protein MW | 80 KD |
| Usage | For Research Use Only! Not for diagnostic or therapeutic procedures. |
| Material Safety Data Sheet | |
| English_US |
|
| Danish |
|
| Dutch |
|
| English_UK |
|
| French |
|
| German |
|
| Spanish |
|
| Norwegian |
|
| Portuguese |
|
| Finnish |
|
| Swedish |
|
| Polish |
|